Language:English
Language:

Xcessbio

Place your promotion here

You have no items in your shopping cart.

MI-2, Menin-MLL Inhibitor

MI-2, Menin-MLL Inhibitor

$119.00
A highly potent and selective small molecule directly binding to MALT1 and irreversibly suppressing its protease function.
Catalog No. Unit Price Qty
M66046-2s 2mg solid $119.00
M66046-2 10 mM in DMSO (0.533 mL) $119.00

Details

Product Information
Molecular Weight: 375.55
Formula: C18H25N5S2
Purity: ≥98%
CAS#: 1271738-62-5
Solubility: DMSO up to 100 mM
Chemical Name: 4-(4-(5,5-dimethyl-4,5-dihydrothiazol-2-yl)piperazin-1-yl)-6-propylthieno[2,3-d]pyrimidine
Storage: Powder: 4oC 1 year. DMSO: 4oC 3 month; -20oC 1 year.

Biological Activity:

MI-2 is a potent and specific Menin-MLL inhibitor with an IC50 ~446 nM. It specifically binds to Menin and inhibits Menin’s interaction with MLL fusion proteins in cells. It can effectively reverse MLL fusion protein–mediated leukemic transformation by downregulating the expression of target genes downstream of MLL fusion protein oncogenic activity. MI-2 is a new tool for better understanding MLL-mediated leukemogenesis and represents a new approach for studying the role of Menin as an oncogenic cofactor of MLL fusion proteins.

 

How to Use:

  • In vitro: MI-2 was used at 10-25 µM concentration in vitro and in the cellular assays. 
  • In vivo: n/a 

 

Reference:

  • 1. Grembecka J, et al. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. (2012) Nat Chem Biol. 8(3):277-84.



 Products are for research use only. Not for human use.

 

Description

Details

Product Information
Molecular Weight: 375.55
Formula: C18H25N5S2
Purity: ≥98%
CAS#: 1271738-62-5
Solubility: DMSO up to 100 mM
Chemical Name: 4-(4-(5,5-dimethyl-4,5-dihydrothiazol-2-yl)piperazin-1-yl)-6-propylthieno[2,3-d]pyrimidine
Storage: Powder: 4oC 1 year. DMSO: 4oC 3 month; -20oC 1 year.

Biological Activity:

MI-2 is a potent and specific Menin-MLL inhibitor with an IC50 ~446 nM. It specifically binds to Menin and inhibits Menin’s interaction with MLL fusion proteins in cells. It can effectively reverse MLL fusion protein–mediated leukemic transformation by downregulating the expression of target genes downstream of MLL fusion protein oncogenic activity. MI-2 is a new tool for better understanding MLL-mediated leukemogenesis and represents a new approach for studying the role of Menin as an oncogenic cofactor of MLL fusion proteins.

 

How to Use:

  • In vitro: MI-2 was used at 10-25 µM concentration in vitro and in the cellular assays. 
  • In vivo: n/a 

 

Reference:

  • 1. Grembecka J, et al. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. (2012) Nat Chem Biol. 8(3):277-84.



 Products are for research use only. Not for human use.

 

Reviews

Write Your Review

How do you rate this product? *

Price:
Value:
Quality: